Antibody Analytics Limited – Trademark Portfolio
Entity Type: 99
Antibody Analytics Limited holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ROUKEN.
Antibody Analytics Discovery Centre,
Braidhurst Industrial, Motherwell, North Lanarkshire ML1 3ST
Showing of trademarks Trademarks
Trademark Classifications
Antibody Analytics Limited's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Antibody Analytics Limited have?
Antibody Analytics Limited has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Antibody Analytics Limited file in?
Antibody Analytics Limited files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Antibody Analytics Limited's most well-known trademarks?
Antibody Analytics Limited's registered trademark portfolio includes well-known marks such as ROUKEN. These are among 1 currently registered trademark in the portfolio.
What is Antibody Analytics Limited's trademark registration success rate?
Antibody Analytics Limited has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.